The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis - Taylor, P; Downie, B; Zhuo, L; Gindin, Y; Tarrant, J; Liu, J; Galien, R; Mirza, A (Wiley, 2018)